Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases
Steren B, Burtness B, Bhatia A, Demirci H, Shinder R, Yoo D, Tse B, Pointdujour-Lim R. Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases. Ophthalmic Plastic And Reconstructive Surgery 2022, 38: 496-502. PMID: 35502804, DOI: 10.1097/iop.0000000000002190.Peer-Reviewed Original ResearchConceptsOrbital squamous cell carcinomaSquamous cell carcinomaCell carcinomaImmune checkpoint inhibitorsMulti-institutional seriesSignificant side effectsCheckpoint inhibitorsPatient characteristicsComplete responseClinical featuresStudy cohortOrbital exenterationCemiplimabDrug dosingSide effectsPatientsCarcinomaTreatmentExenterationRegimenResponseDosingCohortWeeksCessation